BioNTech continued to grow its oncology business by agreeing to buy fellow German biotech CureVac for $1.25 billion in a deal that combines two of the world's leaders in mRNA treatments.

The U.S. Food and Drug Administration on Thursday expanded the use of Moderna's respiratory syncytial virus vaccine to a ...

The BioNTech SE acquisition of CureVac N.V. brings together complementary technologies, as both are developing mRNA ...

For a long time, scientists depended on luck to find new proteins. In 1840, for example, the Friedrich Ludwig Hünefeld, a ...

The health secretary fired all the members of the Advisory Committee on Immunization Practices late on Monday.

BioNTech continued to grow its oncology business by agreeing to buy fellow German biotech CureVac for $1.25 billion in a deal ...

A team led by Professor Won Do Heo from the Department of Biological Sciences, KAIST, has developed a pioneering technology ...

RNA gene scissors (CRISPR-Cas13) are gaining significant attention as a next-generation gene therapy with fewer side effects.

President Trump’s administration has slammed the brakes on development of messenger RNA (mRNA) vaccines, which proved their ...

The personalized CRISPR treatment could be the future of gene therapy, but hurdles remain before everyone has access.

The finding clarifies an important aspect of cell biology, and may have clinical implications, since this messenger RNA modification, known as m6A, is the target of an emerging class of cancer ...

The researchers spent more than six years developing novel methods to target messenger RNA in blood and then used it to identify the presence of cancers at different stages, to track resistance to ...